JPMorgan analyst Jeffrey Zekauskas downgraded H.B. Fuller (FUL) to Neutral from Overweight with an unchanged price target of $51. The analyst views the shares as valued fairly at current levels and sees better opportunity in semi-commodity peers such as Eastman Chemical (EMN), Cabot (CBT) or Ashland (ASH). He says the other names offer a higher free cash flow yield, lower leverage or lower enterprise value to EBITDA multiples. Volume growth at H.B. Fuller has slowed with the global economy, particularly in China, Europe and the United States, Zekauskas tells investors in a research note.